Cediranib
Primary Peritoneal Carcinosarcoma
Mayo ClinicSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Primary Peritoneal Carcinosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Mayo Clinic | Phase 2 | B |
Inno-206 National Cancer Institute (NCI) | Phase 2 | B |
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Mayo Clinic | Phase 2 | B |
Irinotecan Roswell Park Cancer Institute | Phase 2 | B |
(+)-VINCRISTINE Roswell Park Cancer Institute | Phase 2 | B |
View all 16 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →